Bioequivalence and Bioavailability Forum

❝ All of the product-specific guidances contain a section ‘Explanation’. See also Yu et al.

OK

❝ ❝ Further, can we perform crossover studies for NTI by taking extra safety measurement in to the study?

❝

❝ You can. Whether that is necessary in healthy volunteers depends on the drug.

Yes.

❝ ❝ Further, what is the BE limit for such drugs?

❝

❝ It depends on \(\small{s_{wR}}\) observed in the study, i.e., reference-scaling is applied. Furthermore – irrespective of passing the scaled limits – the study has to pass 80.00–125.00% as well and the upper confidence limit of \(\small{\sigma_{wT}/\sigma_{wR}}\) has to be ≤2.5.

its common for all NTI or its varies from drug to drug?

---

Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Helmut]